RE:H.C. Wainwright has a US$15 target for AEZS"these price specifications are usually worth nothing!"
Human growth hormone deficiency can be a very serious condition that can retard growth, affect quality of life, and lifespan. The diagnosis of this condition isn't going away and no one would want their child to needlessly suffer. When you have the one and only dedicated diagnostic test for human growth hormone deficiency, as AEZS does, forecasting should generally be relatively easy compared to a test where there is direct competition and the medical condition isn't serious. The number of tests per year is generally known. The test is already approved in Europe and by the FDA and is understood in real world conditions.
Novo Nordisk paid ~$250 million(upfront, equity) plus tiered royalties without approval for the childhood market. H.C Wainwright's US$15 target is about half that value and that would leave no value for any preclinical programs moving into Phase I. H.C. Wainwright's target was also set before the recent surge in biotech.
Gilles is on the Board of Directors of AEZS and should have a very good idea concerning the level of interest and expected terms of a new North American deal. Gilles has an edge over the market.
"Further, based upon our active outreach and discussions, we expect to secure an alternate development and commercialization partner for Macrilen® for the U.S. and Canada.” July 13, 2023; AEZS news release